Italian iTTP Registry

Recruiting now

Conditions studied: TTP - Thrombotic Thrombocytopenic Purpura

In brief

ItaliTTP is an observational, prospective, single-arm, national, multicenter, non-pharmacological cohort study aimed at better defining and understanding the natural history, disease severity, and clinical outcomes of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in Italy. A minimum of 132 consecutive patients with acute iTTP (first event or relapse) will be enrolled for 3 years, with the possibility of extension, with a follow-up period of 3 years.

Key facts

Study ID

NCT06376786

Run by

Fondazione Luigi Villa

People needed

132

Starts

2024-06-20

Expected to finish

2030-05-31

Last updated by the study team

2024-07-10

Who can join

Age: 12 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with an acute iTTP episode (first event or relapse), defined by thrombocytopenia and microangiopathic hemolytic anemia, in the absence of alternative causes, and the presence of severe deficiency of ADAMTS13 activity (< 10 IU/dL or <10% of normal value) and anti-ADAMTS13 autoantibodies
• Both male and female patients, aged 12 years or older
• Patients who have signed the informed consent for the participation to the study

You may not qualify if…

• Patients who have not signed the informed consent for the participation to the study

Where it is running

• Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, MI, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.